Global Diabetes Drugs Market

Global Diabetes Drugs Market
is projected to reach US$
106.65 Billion by 2030
Base Year: 2022
Market Research & Advisory

2
2
Renub Research has recently published a report named "Global Diabetes Drugs Market: Global Industry Trends,
Share, Size, Growth, Opportunity, and Forecast 2023-2030," providing a detailed industry analysis that consists
of market share insights. Furthermore, the report encompasses a study of competitors and regions and the recent
growth in the Global Diabetes Drugs Market.
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/diabetes-
drug-market-p.php
Global Diabetes Drugs Market is foreseen to expand at a CAGR of 5.49% from 2023 to 2030. Diabetes is a global
epidemic with significant demand for diabetes drugs. According to World Health Organisation (WHO), the prevalence
of diabetes is increasing worldwide, with an estimated 537 million adults affected in 2022, projected to rise to 783
million by 2045. This chronic disease affects the body energy metabolism and can lead to severe complications such
as heart disease, stroke, blindness, kidney failure, and amputations. However, with proper management, individuals
with diabetes can lead long and healthy lives.
2
https://www.renub.com

3
3
With various types of diabetes, including type 1, type 2, and gestational diabetes, it affects the body's ability to
regulate blood sugar levels. Type 1 diabetes requires lifelong insulin therapy, while type 2 diabetes is often
associated with insulin resistance and lifestyle factors. Gestational diabetes occurs during pregnancy but can
increase the risk of type 2 diabetes later in life. Common symptoms include excessive thirst, frequent urination,
weight loss, and fatigue. Badly managed diabetes can lead to momentous complications. Management involves
lifestyle modifications and medications such as insulin and oral antidiabetic drugs. Regular monitoring, check-ups,
and education are essential for effective diabetes management.
The future of the global diabetes drugs market looks promising due to factors like increasing prevalence of type 2
diabetes, advancements in research and development, personalized medicine approaches, improved awareness
and education, digital health technologies, collaborations, favorable reimbursement policies, government initiatives,
and increased healthcare spending in emerging markets. These factors will drive the demand for effective
treatments, innovation, optimized therapeutic outcomes, improved diagnosis and treatment rates, real-time
monitoring, self-care, treatment optimization, and better access to healthcare services and affordable medications
for effective diabetes management.
3

4
4
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=diabetes-
drug-market-p.php
Type 1 Diabetes dominates the global diabetes drugs market.
According to the Lancet Diabetes & Endocrinology, global type 1 diabetes (T1D) cases are projected to increase
from 8.4 million in 2021 to 13.5-17.4 million by 2040. The dominance of type 1 diabetes in the global diabetes drugs
market is attributed to its chronic nature, requiring lifelong insulin treatment, and creating a consistent demand for
diabetes drugs. The intensive management and monitoring of type 1 diabetes further contribute to the reliance on
medication. The lower prevalence of type 1 diabetes compared to type 2 diabetes allows for a more targeted market
for specialized diabetes drugs.
Disease Type – Global Diabetes Drug Market has been covered from 2 viewpoints:
1. Type 1 Diabetes Drug Market 2. Type 2 Diabetes Drug Market
4

5
5
Insulin dominates the global diabetes drug market by managing type 1 diabetes and being used for some
with type 2 diabetes.
The high prevalence of both diabetes types drives the significant demand for insulin. Its longstanding effectiveness,
reputation, and trust among healthcare professionals and patients make it a preferred treatment option. Insulin
continuous need for managing chronic diabetes and its advancements in formulations and delivery methods,
including analogs, offer tailored treatment options. The existing manufacturing and distribution infrastructure, along
with patent protection and regulatory requirements, create barriers for new entrants, solidifying insulin's dominant
position in the global diabetes drugs market.
Therapy –Global Diabetes Drugs Market have been covered from 3 viewpoints:
1. Oral 2. Injection 3. Insulin
DPP-IV inhibitors' leadership in the global diabetes drugs market is attributed to their flexibility, extensive
research, and medical association endorsements.
5

6
6
DPP-IV inhibitors effectively manage type 2 diabetes by regulating blood
sugar levels through increased insulin secretion and reduced glucagon levels. With
oral administration, favorable side effects, and flexibility in treatment approaches,
they are preferred by healthcare professionals. Extensive research has resulted in a
diverse portfolio, allowing tailored treatment options. Supported by clinical evidence
and endorsed by medical associations, DPP-IV inhibitors lead the global diabetes
drugs market for type 2 diabetes management.
Oral- Global Diabetes Drugs Market have been covered from 5 viewpoints.
1. Oral (DPP) IV inhibitor
2. SGLT – 2
3. Alpha Glucosidase Inhibitor
4. Biguanide
5. Others Oral Drug
6

7
7
Glucagon-like peptide (GLP-1) agonists' hegemony in the global diabetes drug
market.
Glucagon-like peptide (GLP-1) agonists offer additional benefits such as weight loss,
appetite reduction, and improved cardiovascular health, making them preferred for
comprehensive diabetes management. With various administration options available,
including injections and oral medications, GLP-1 agonists provide flexibility and
enhance patient compliance. Extensive research and development efforts have
resulted in a diverse range of drugs within this class, enabling personalized treatment
plans. Clinical trials and real-world evidence consistently demonstrate the efficacy
and safety of GLP-1 agonists, solidifying their widespread adoption.
Injection – Global Diabetes Drugs Market is covered from 2 viewpoints.
1. Glucagon-like peptide (GLP) 1 agonist
2. Amylin receptor agonist
7

8
8
Long-acting insulinhas significant share in the global diabetes drugs market is due to its ability to provide
steady and prolonged insulin release for stable blood sugar control.
Long-acting insulin's flexible dosing options cater to individual patient needs, either as a standalone therapy or in
combination with other drugs. The long history of safe and effective use has instilled confidence among healthcare
professionals and patients. Also, the availability of various formulations, including improved insulin analogs,
enhances convenience and administration. The high prevalence of diabetes, especially type 2, fuels the demand for
long-acting insulin, while its well-established manufacturing and distribution infrastructure, along with patent
protection and regulatory requirements, present barriers to new competitors, consolidating its significant market
share.
Insulin - Global Diabetes Drugs Market is covered from 4 viewpoints.
1. Rapid – Acting Insulin
2. Long - Acting Insulin
3. Premixed Insulin
4. Other Insulin
8

9
9
United States has the highest share in the global diabetes drugs market.
The United States takes the lead in the global diabetes drugs market, primarily due to its substantial diabetes
prevalence, advanced healthcare infrastructure, thriving pharmaceutical industry, robust research and development
capabilities, prominent presence of pharmaceutical companies and healthcare providers, favorable reimbursement
policies, and comprehensive insurance coverage.
According to the National Diabetes Statistics Reportin 2022, approximately 37.3 million Americans, accounting for
around 11.3% of the population, are living with diabetes, and the country exhibits a significant demand for diabetes
drugs. These factors collectively enable patients in the United States to access a wide range of medications and
treatment options promptly and contribute to the nation's prominence in the global diabetes drugs market.
9

10
10
Countries – Global Diabetes Drugs Market is covered in 24 viewpoints.
1. United States 2. Canada 3. France 4. Germany
5. Italy 6. Spain 7. UK 8. Mexico
9. Brazil 10. Japan 11. South Korea 12. China
13. India 14. Australia 15. Vietnam 16. Malaysia
17. Indonesia 18. Philippines 19. Thailand 20. Saudi Arabia
21. Iran 22. Egypt 23. Oman 24. South Africa
Competitive Landscape.
Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb Co., and Novartis
AG are key players in the global diabetes drug market, contributing significantly to its development and growth.
10

11
11
Company Insights:
• Overview • Recent Development & Strategies • Financial Insights
Key Players Analysis
1. Novo Nordisk 2. AstraZeneca plc 3. Biocon
4. Sanofi 5. Eli Lilly 6. Johnson & Johnson
7. Bristol Myers Squibb Co. 8. Novartis AG
11

S
O U T
A U
B
12
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in
Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy,
organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000
syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to
EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings
and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research

Global Diabetes Drugs Market

Recommended

Recommended

More Related Content

Similar to Global Diabetes Drugs Market

Similar to Global Diabetes Drugs Market (20)

More from Renub Research

More from Renub Research (20)

Recently uploaded

Recently uploaded (20)

Global Diabetes Drugs Market